Published On: Mon, Sep 26th, 2016

Israeli Start Up is FDA Clear for Upright Imaging Solution in Proton Therapy Enhancement

Patients who will initially benefit from this technology will be those treated for cancers of the lung, breast, chest, the head and neck, and lower torso.



P-Cure Ltd., an Israeli startup for proton therapy has received U.S. Food and Drug Administration (FDA) approval for its patented upright imaging solution. The P-Cure system is based on a diagnostic-quality computed tomography (CT) enabling treatment for cancer patients in a seated position.

P-Cure’s first product was cleared by the FDA in 2010.

“The benefits of treating patients in a seated position include greater patient comfort, less internal organ movement, better saliva drainage and a better position for breathing for asthmatic and other patients experiencing impaired breathing. It may also deliver less collateral radiation to sensitive organs while enabling greater accuracy in proton beam delivery, ” Said Michael Marash, Ph.D., founder and CEO of P-Cure.

In addition, the company said in a press release, there are also significant economic advantages to treating patients in a seated position including the capital cost of equipment and construction, .



Read more about: , ,

Wordpress site Developed by Fixing WordPress Problems